Primary Care POC Diagnostics Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Primary Care POC Diagnostics Market size was valued at USD 18.3 billion in 2023 and is estimated to expand at 7% CAGR from 2024 to 2032. Point-of-care (POC) diagnostics in primary care refer to medical tests or diagnostic procedures that are performed at or near the location wherein patient care is provided, typically in a primary care setting such as a doctor's office, clinic, or community health center.
The primary goal of POC diagnostics is to obtain rapid and accurate diagnostic information, enabling healthcare providers to make immediate decisions about patient care. The increasing incidence of infectious diseases and chronic conditions including cardiovascular diseases is one of the major factors driving the demand for primary care POC diagnostics market progress. For instance, according to the World Health Organization (WHO) report, in 2021, there were around 37.7 million individuals suffering with human immunodeficiency virus (HIV).
Furthermore, the growing prevalence of diabetes worldwide is a significant factor contributing to increasing point of care testing, which is estimated to account for over USD 78 billion by 2032, at home-care settings. Additionally, as per statistics, approximately 537 million adults were individuals suffering from diabetes in 2021. Diabetic foot ulcers and pressure ulcers are a common complication and are a major cause of hospital admissions in people with diabetes. Thus, this growing prevalence of diabetes is anticipated to boost demand of primary care POC diagnostics and thereby accelerate market expansion.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Primary Care POC Diagnostics Market size in 2023: | USD 18.3 Billion |
| Forecast Period: | 2024 –2032 |
| Forecast Period 2023 - 2032 CAGR: | 7 |
| 2023 Value Projection: | USD 33.6 Billion |
| Historical Data for: | 2018 – 2023 |
| No of Pages: | 180 |
| Tables, Charts & Figures: | 482 |
| Segments Covered: | Product, End-use, and Region |
| Growth Drivers: |
|
| Pitfalls Challenges: |
|
The increasing technological advancements in the primary care POC diagnostics market is projected to augment significant industry expansion. Current trend in the industry is strongly persuaded towards smart devices equipped with mobile healthcare that will significantly accelerate growth of remote patient monitoring and management. Wide range of mobile healthcare technologies have been developed, of which cell phone-based point of care technologies has become the most prominent technology.
The primary care POC diagnostics market by product is categorized into glucose monitoring, cardiometabolic testing products, infectious disease testing products, coagulation testing products, pregnancy and fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drug-of-abuse (DoA) testing products, fecal occult testing products, and other products. The glucose monitoring segment garnered USD 4.5 billion revenue size in the year 2023.
Based on end-use, the primary care POC diagnostics market is segmented into hospitals, diagnostic centers, research laboratories, home care settings, and other end-users. The hospitals segment garnered USD 6.5 billion revenue size in the year 2023.
U.S. primary care POC diagnostics market accounted for USD 6.9 billion revenue size in 2023 and is predicted to witness substantial market growth over the analysis timeline.
The primary care POC diagnostics industry is consolidated, with key players including, Abbott Laboratories, BioMerieux SA, Bio-Rad Laboratories, and others dominating the market space. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market share.
For instance, in October 2021, Bio-Rad Laboratories launched new CFX Opus 96 Dx System and the CFX Opus 384 Dx System, real-time PCR detection systems. This system offers precise quantification to improve assay development, workflow efficiencies and productivity for diagnostic testing and research. This strategy improved diagnostic test outcomes and enabled in augmenting revenue growth.
Some of the eminent market participants operating in the primary care POC diagnostics industry include:
By Product, 2018 – 2032 (USD Million)
By End-use, 2018 – 2032 (USD Million)
The above information is provided for the following regions and countries:
The global primary care POC diagnostics industry was valued at USD 18.3 billion in 2023 and is estimated to reach USD 33.6 billion by 2032, owing to the increasing incidence of infectious diseases and chronic conditions including cardiovascular diseases.
The glucose monitoring segment garnered USD 4.5 billion revenue size in the year 2023, driven by the increasing adoption of portable, high convenience, and cost-effectiveness as well as rapid primary POC glucose tests.
U.S. primary care POC diagnostics market accounted for USD 6.9 billion revenue size in 2023 and is predicted to witness substantial growth through 2032, attributed to the increasing government initiatives towards chronic and infectious diseases.
Abbott Laboratories., Sysmex Corporation., ACON Laboratories, Inc., Siemens Healthineers AG., Becton, Dickinson, and Company, Nova Biomedical., BioMerieux SA, Bio-Rad Laboratories, Inc, HemoCue AB (Danaher Corporation)., Dexcom, Inc., HemoCue AB (Danaher Corporation) and Dragerwerk Ag & Co.